OA11291A - Combination therapy comprising atorvastatin and anantihypertensive agent. - Google Patents

Combination therapy comprising atorvastatin and anantihypertensive agent. Download PDF

Info

Publication number
OA11291A
OA11291A OA1200000040A OA1200000040A OA11291A OA 11291 A OA11291 A OA 11291A OA 1200000040 A OA1200000040 A OA 1200000040A OA 1200000040 A OA1200000040 A OA 1200000040A OA 11291 A OA11291 A OA 11291A
Authority
OA
OAPI
Prior art keywords
pharmaceutical composition
agent
sait
pharmaceutically acceptable
prepared
Prior art date
Application number
OA1200000040A
Other languages
English (en)
Inventor
Robert Andrew Donald Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11291A publication Critical patent/OA11291A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Pyrrole Compounds (AREA)
OA1200000040A 1997-08-29 2000-02-18 Combination therapy comprising atorvastatin and anantihypertensive agent. OA11291A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
OA11291A true OA11291A (en) 2003-08-25

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000040A OA11291A (en) 1997-08-29 2000-02-18 Combination therapy comprising atorvastatin and anantihypertensive agent.

Country Status (41)

Country Link
US (2) US20020099046A1 (enExample)
EP (1) EP1009400B1 (enExample)
JP (2) JP2001514223A (enExample)
KR (3) KR20030015394A (enExample)
CN (3) CN1268053A (enExample)
AP (1) AP1191A (enExample)
AR (1) AR016399A1 (enExample)
AT (1) ATE285767T1 (enExample)
AU (1) AU740424B2 (enExample)
BG (1) BG64724B1 (enExample)
BR (1) BR9811556A (enExample)
CA (1) CA2296723A1 (enExample)
CO (1) CO4970724A1 (enExample)
DE (1) DE69828413T2 (enExample)
DZ (1) DZ2595A1 (enExample)
EA (1) EA200000012A1 (enExample)
EG (1) EG24678A (enExample)
ES (1) ES2234134T3 (enExample)
GT (1) GT199800126A (enExample)
HR (1) HRP980474A2 (enExample)
HU (1) HUP0004318A3 (enExample)
ID (1) ID24118A (enExample)
IL (2) IL133962A0 (enExample)
IS (1) IS5341A (enExample)
MA (1) MA26536A1 (enExample)
MY (1) MY121008A (enExample)
NO (1) NO323987B1 (enExample)
NZ (2) NZ530630A (enExample)
OA (1) OA11291A (enExample)
PA (1) PA8457901A1 (enExample)
PE (1) PE107099A1 (enExample)
PL (1) PL339091A1 (enExample)
PT (1) PT1009400E (enExample)
SA (1) SA98190603B1 (enExample)
SK (1) SK1432000A3 (enExample)
TN (1) TNSN98155A1 (enExample)
TR (1) TR200000563T2 (enExample)
UY (1) UY25155A1 (enExample)
WO (1) WO1999011260A1 (enExample)
YU (1) YU2000A (enExample)
ZA (1) ZA987839B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830887A (en) 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
EE05670B1 (et) 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
US7125897B1 (en) 1999-09-24 2006-10-24 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
US20030207930A1 (en) 2000-07-19 2003-11-06 Erwin Marti Valsartan salts
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
UA76475C2 (en) * 2001-07-19 2006-08-15 Pharmacia Corp Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
CA2490636A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
CA2492060C (en) * 2002-06-27 2011-11-01 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
AU2003251627A1 (en) * 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20060051418A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
ZA200706702B (en) * 2005-02-17 2008-11-26 Chiesi Farma Spa Therapeutic combinations of manidi pine and a statin
CN101415425B (zh) 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
MX2009004681A (es) * 2006-10-30 2009-08-19 Hanall Pharmaceutical Co Ltd Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
US9161933B2 (en) * 2009-01-23 2015-10-20 Hanmi Science Co., Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
NZ731751A (en) 2014-10-23 2023-07-28 Arena Pharm Inc Method of treating conditions related to the pgi2 receptor
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
AU2017274438A1 (en) * 2016-06-02 2018-12-13 Ana Pharmaceuticals, Inc. Methods and compositions for treatment of hypercalciuria and nephrolithiasis
MX2019008813A (es) 2017-01-25 2020-02-12 The George Inst For Global Health Composiciones para el tratamiento de la hipertension.
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
WO2019222764A1 (en) 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
EP3826633A4 (en) * 2018-07-26 2022-04-27 The George Institute For Global Health COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration

Also Published As

Publication number Publication date
NZ502280A (en) 2002-11-26
KR20010022477A (ko) 2001-03-15
KR20030015394A (ko) 2003-02-20
US20030199492A1 (en) 2003-10-23
IL133962A (en) 2006-07-05
BG64724B1 (bg) 2006-01-31
US20020099046A1 (en) 2002-07-25
EP1009400A1 (en) 2000-06-21
DE69828413D1 (de) 2005-02-03
WO1999011260A1 (en) 1999-03-11
BG104075A (en) 2000-09-29
EP1009400B1 (en) 2004-12-29
HUP0004318A2 (hu) 2001-05-28
HUP0004318A3 (en) 2002-10-28
ES2234134T3 (es) 2005-06-16
YU2000A (sh) 2002-12-10
PE107099A1 (es) 1999-11-06
MY121008A (en) 2005-12-30
BR9811556A (pt) 2000-08-22
AP9801332A0 (en) 1998-09-30
ATE285767T1 (de) 2005-01-15
AP1191A (en) 2003-07-19
NO20000996D0 (no) 2000-02-28
NZ530630A (en) 2005-05-27
CO4970724A1 (es) 2000-11-07
JP2005041875A (ja) 2005-02-17
ID24118A (id) 2000-07-06
IL133962A0 (en) 2001-04-30
NO323987B1 (no) 2007-07-30
CN1473566A (zh) 2004-02-11
SK1432000A3 (en) 2000-12-11
UY25155A1 (es) 2000-12-29
AU740424B2 (en) 2001-11-01
AU8458998A (en) 1999-03-22
TNSN98155A1 (fr) 2005-03-15
CN1473567A (zh) 2004-02-11
EA200000012A1 (ru) 2000-08-28
CA2296723A1 (en) 1999-03-11
AR016399A1 (es) 2001-07-04
KR20040106591A (ko) 2004-12-17
EG24678A (en) 2010-04-27
NO20000996L (no) 2000-04-27
PL339091A1 (en) 2000-12-04
PA8457901A1 (es) 2000-05-24
GT199800126A (es) 2000-01-29
IS5341A (is) 2000-01-14
ZA987839B (en) 2000-02-28
CN1268053A (zh) 2000-09-27
TR200000563T2 (tr) 2000-07-21
SA98190603B1 (ar) 2006-07-04
JP2001514223A (ja) 2001-09-11
MA26536A1 (fr) 2004-12-20
PT1009400E (pt) 2005-02-28
DE69828413T2 (de) 2005-12-08
DZ2595A1 (fr) 2003-02-22
HRP980474A2 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
AP1191A (en) Combination therapy.
AP1207A (en) Combination therapy.
US20030162824A1 (en) Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
UA56363C2 (uk) Спільна сіль амлодипіну та аторвастатину, фармацевтична композиція та спосіб лікування (варіанти)
EP1045691B1 (en) Statin-carboxyalkylether combinations
AU784119B2 (en) Combination therapy comprising atorvastatin and an antihypertensive agent
US20050261275A1 (en) Therapeutic combination
EP1280522B1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
EP1514543A1 (en) Combination therapy comprising atorvastatin and an antihypertensive agent
CZ2000342A3 (cs) Kombinační terapie zahrnující atorvastatin a antihypertensní činidlo
CA2299397A1 (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030225123A1 (en) Antihypertensive agents and use
ZA200208131B (en) Antihypertensive agents and use.
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound
EP1481962A1 (en) New cholesterolemia-lowering carboxyalkylether compound
MXPA00002105A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations